Stock listing

gettex:YAG Atossa Therapeutics, Inc. Aktie

German listing (gettex) of Atossa Therapeutics, Inc. · home listing NASDAQ:ATOS

Follow Atossa Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ATOS

$1.60 USD -0.22 (-11.9%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ATOS

Past year -85.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.59 – $1.72 USDNov 20, 2026
Volume
48,911 sharesNov 20, 2026
Market cap
$15.92M USDAt the close on Nov 20, 2026 · price × 9.98M shares outstanding
52-week range
$1.59 – $14.85 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$161,555 USDMedian day 54,625 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Atossa Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ATOS · Home$1.595 USD-0.215 (-11.9%)48,911$1.72$1.72$1.59$1.81Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ATOS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.595-0.215-11.9%$1.72$1.72$1.5948,911
$1.81-0.09-4.7%$1.85$1.92$1.7943,783
$1.90-0.03-1.6%$1.90$2.003$1.84246,482
$1.93-0.03-1.5%$1.98$2.09$1.8669,553
$1.96+0.02+1.0%$1.91$2.00$1.8556,354
$1.94-0.09-4.4%$2.03$2.059$1.8191,448
$2.03-0.11-5.1%$2.17$2.189$2.0341,464
$2.14+0.01+0.5%$2.12$2.31$2.07655,558
$2.13+0.01+0.5%$2.15$2.20$2.11240,134
$2.12+0.10+5.0%$1.99$2.19$1.9934,371
$2.02-0.10-4.7%$2.12$2.121$1.9875,033
$2.12-0.21-9.0%$2.33$2.35$2.1070,186
$2.33+0.03+1.3%$2.31$2.35$2.2726,078
$2.30+0.13+6.0%$2.21$2.40$2.20565,998
$2.17-0.06-2.7%$2.25$2.43$2.1432,903
$2.23-0.14-5.9%$2.35$2.375$2.2268,006
$2.37-0.01-0.4%$2.38$2.425$2.3629,410
$2.38-0.07-2.9%$2.44$2.628$2.3724,830
$2.45-0.15-5.8%$2.58$2.58$2.4035,077
$2.60-0.12-4.4%$2.74$2.85$2.6077,024
$2.72+0.19+7.5%$2.49$2.77$2.4690,656
$2.53-0.01-0.4%$2.53$2.585$2.38189,632
$2.54-0.02-0.8%$2.54$2.67$2.5136,755
$2.56-0.35-12.0%$2.66$2.76$2.5180,522
$2.91+0.26+9.8%$2.59$2.95$2.51104,625
$2.65-0.13-4.7%$2.78$3.12$2.53227,027
$2.78+0.22+8.6%$2.52$2.81$2.45238,706
$2.56+0.171+7.2%$2.35$2.60$2.3071,414
$2.389-0.051-2.1%$2.44$2.53$2.33581,419
$2.44+0.02+0.8%$2.45$2.74$2.12265,612
$2.42-0.04-1.6%$2.46$2.478$2.385101,012
$2.46+0.01+0.4%$2.41$2.49$2.4119,070
$2.450.000.0%$2.46$2.54$2.4354,625
$2.45+0.11+4.7%$2.38$2.50$2.34153,315
$2.34+0.07+3.1%$2.23$2.379$2.1774,271
$2.27+0.32+16.4%$1.96$2.30$1.96113,600
$1.95-0.04-2.0%$1.99$2.15$1.9567,768
$1.99+0.03+1.5%$2.06$2.16$1.9683,318
$1.96+0.06+3.2%$1.905$2.04$1.82152,932
$1.90-0.15-7.3%$2.06$2.065$1.8977,843
$2.05-0.13-6.0%$2.15$2.22$2.0537,461
$2.18-0.08-3.5%$2.25$2.26$2.1537,187
$2.26+0.01+0.4%$2.25$2.43$2.25129,526
$2.25+0.03+1.4%$2.25$2.39$2.2567,169
$2.22-0.18-7.5%$2.37$2.38$2.2239,755
$2.40-0.02-0.8%$2.42$2.43$2.3733,288
$2.42+0.05+2.1%$2.39$2.48$2.3945,776
$2.37-0.11-4.4%$2.475$2.49$2.3743,779
$2.48-0.03-1.2%$2.53$2.555$2.4535,039
$2.51+0.17+7.3%$2.36$2.54$2.3660,410
$2.34-0.06-2.5%$2.36$2.61$2.3347,238
$2.40-0.115-4.6%$2.54$2.54$2.4024,800
$2.515-0.005-0.2%$2.49$2.587$2.44541,370
$2.52-0.01-0.4%$2.51$2.60$2.5028,028
$2.53+0.07+2.8%$2.50$2.60$2.4656,692
$2.46+0.04+1.7%$2.40$2.51$2.3944,771
$2.42-0.08-3.2%$2.48$2.50$2.31792,004
$2.50-0.08-3.1%$2.57$2.59$2.5053,194
$2.58-0.06-2.3%$2.62$2.62$2.5049,003
$2.64-0.01-0.4%$2.64$2.69$2.58523,115
$2.65-0.03-1.1%$2.66$2.70$2.6126,301
$2.68+0.04+1.5%$2.62$2.69$2.5849,690
$2.64+0.10+3.9%$2.56$2.65$2.4557,149
$2.54-0.05-1.9%$2.59$2.62$2.5125,656
$2.59-0.05-1.9%$2.62$2.62$2.4470,954

Splits

3 splits since 2016 · NASDAQ:ATOS · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
1-for-12Consolidation
1-for-15Consolidation
Ticker
gettex:YAG
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Atossa Therapeutics, Inc. news

Atossa Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
29 in the last 12 months · 186 in all · newest Nov 10, 2026 · oldest 2019
Calls
4 calls with a replay · 4 with a transcript · latest Mar 25, 2025
Decks
9 decks · latest September 2026

Where Atossa Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ATOS · Home listingNASDAQUnited StatesUSD
BMV:ATOSBMVMexicoMXN
Tradegate:YAGTradegateGermanyEUR
gettex:YAG · This pagegettexGermanyEUR
LS Exchange:A2JJ99LS ExchangeGermanyEUR
BIVA:ATOSBIVAMexicoMXN
BOATS:ATOSBOATSUnited StatesUSD
Lang & Schwarz:A2JJ99Lang & SchwarzGermanyEUR
LS Exchange:A41ZVBLS ExchangeGermanyEUR
Dusseldorf:YAGDusseldorfGermanyUSD
Frankfurt:YAGFrankfurtGermanyEUR
Lang & Schwarz:A41ZVBLang & SchwarzGermanyEUR
Munich:YAGMunichGermanyEUR

Valuation

Price/book 0.7× against a median of 1.7×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$4.66M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.87

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.76MUS$15.67Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
Lipocine Inc. · NASDAQ:LPCNUS$16.39M−US$5.07Mn/a−1.4×n/a0.8×−249.2%0.0×1.18
MaaT Pharma · EURONEXT:MAATUS$16.11MUS$23.36Mn/a4.7×n/an/a−686.6%n/an/a
Elicera Therapeutics AB · OMXSTO:ELICUS$16.11MUS$10.42Mn/an/an/a2.9×n/a0.0×n/a
Pasithea Therapeutics Corp. · NASDAQ:KTTAUS$16.00M−US$25.22Mn/an/a−0.1×0.4×n/a0.0×0.97
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
Median of the othersUS$16.25MUS$11.52M3.7×−0.1×1.7×−213.8%0.0×1.18

Forecasts

1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
19.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.56 · 1 analyst

Team and board

OfficerRole
Steven QuayChief Executive Officer
Mark DanielChief Financial Officer
Janet R. ReaSenior Vice President, R&D

Events

Results days

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open+0.5%
Q2 2026Aug 7, 2026−2.1%
Q1 2026May 8, 2026 · Before open−1.2%
Q4 2025Mar 26, 2026−12.9%
Q3 2025Nov 12, 2025 · Before open−1.7%
Q2 2025Aug 12, 2025 · Before open+1.2%
Q1 2025May 13, 2025 · Before open+6.3%
Q4 2024Mar 31, 2025 · Before open−3.4%
Q3 2024Nov 12, 2024 · Before open−7.4%
Q2 2024Aug 12, 2024 · Before open+6.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open−2.0%
Q4 2023Mar 28, 2024 · Before open−1.6%
Q3 2023Nov 13, 2023 · Before open−0.6%
Q2 2023Aug 14, 2023 · Before open−8.3%
Q1 2023May 15, 2023 · Before open+0.3%
Q4 2022Mar 22, 2023 · After close−5.1%
Q3 2022Nov 7, 2022 · After close−4.4%
Q2 2022Aug 8, 2022 · After close−6.7%
Q1 2022May 9, 2022 · After close+3.6%
Q4 2021Feb 28, 2022 · After close+6.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck29 slidesSeptember 2026
Atossa Genetics — Corporate Update (September 2018)Corporate update25 slidesSep 13, 2018
Atossa Genetics — IPO Roadshow (May 2018)IPO roadshow30 slidesMay 16, 2018
Atossa Genetics — Investor Presentation (February 2018)Investor deck31 slidesFeb 21, 2018
Atossa Genetics — Corporate Update (February 2018)Corporate update31 slidesFeb 1, 2018
Atossa Genetics — Corporate Update (October 2017)Corporate update51 slidesOct 25, 2017
Atossa Genetics — Corporate Update (September 2017)Corporate update34 slidesSep 14, 2017
Atossa Genetics — Investor Presentation (July 2016)Investor deck21 slidesJul 27, 2016
Atossa Genetics — Investor Presentation (January 2015)Investor deck19 slidesJan 15, 2015

Open Decks

Financings

RaiseDate
Registered direct offering of common stock (or common stock equivalents) with Series A and Series B warrants
Closed: US$4.5M raised · Series A and Series B warrants exercisable six months after issuance; Series A expire… · Rodman & Renshaw LLC
Dealers: Rodman & Renshaw LLC (lead)
Use of proceeds: Clinical development of product candidates, working capital and general corporate purposes
Jun 12, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as ATOSSA GENETICS INC. Priced at US$5.00 a share on Nov 7, 2012.

Price
US$5.00 a share
Shares offered
800,000 shares of common stock
Offering size
US$4 million
Underwriters' option
Up to 120,000 more shares
Underwriter
DAWSON JAMES SECURITIES, INC.
Shares delivered
On or about Nov 13, 2012

Steps

StepWhen
Filed publiclyFeb 14, 2012
Amended 12 timesNewest Nov 6, 2012
Shares registered with an exchangeJul 24, 2012
Declared effective by the SECNov 7, 2012
Final prospectus, with the priceNov 9, 2012

Filings

FilingFiled
424B4 · ProspectusNov 9, 2012
CERTNAS · Nasdaq's certificate of listingNov 7, 2012
EFFECT · Notice that a registration is effectiveNov 7, 2012
S-1/A · Registration statement, amendedNov 6, 2012
CORRESP · Letter to the SECNov 5, 2012
CORRESP · Letter to the SECNov 5, 2012
CORRESP · Letter to the SECOct 26, 2012
CORRESP · Letter to the SECOct 26, 2012
S-1/A · Registration statement, amendedOct 25, 2012
CORRESP · Letter to the SECOct 19, 2012
All 40 filings
FilingFiled
S-1/A · Registration statement, amendedOct 19, 2012
UPLOAD · Letter from the SECOct 16, 2012
S-1/A · Registration statement, amendedOct 4, 2012
CORRESP · Letter to the SECOct 3, 2012
FWP · Free writing prospectusSep 13, 2012
CORRESP · Letter to the SECSep 12, 2012
CORRESP · Letter to the SECSep 12, 2012
CORRESP · Letter to the SECSep 10, 2012
CORRESP · Letter to the SECSep 7, 2012
S-1/A · Registration statement, amendedAug 30, 2012
S-1/A · Registration statement, amendedAug 21, 2012
CORRESP · Letter to the SECAug 13, 2012
S-1/A · Registration statement, amendedAug 13, 2012
8-A12B · Registration of shares for listing on an exchangeJul 24, 2012
CORRESP · Letter to the SECJul 24, 2012
CORRESP · Letter to the SECJul 20, 2012
CORRESP · Letter to the SECJun 25, 2012
S-1/A · Registration statement, amendedJun 25, 2012
UPLOAD · Letter from the SECJun 19, 2012
CORRESP · Letter to the SECJun 18, 2012
S-1/A · Registration statement, amendedJun 18, 2012
UPLOAD · Letter from the SECJun 13, 2012
CORRESP · Letter to the SECJun 11, 2012
S-1/A · Registration statement, amendedJun 11, 2012
UPLOAD · Letter from the SECJun 6, 2012
S-1/A · Registration statement, amendedMay 21, 2012
UPLOAD · Letter from the SECApr 20, 2012
S-1/A · Registration statement, amendedApr 6, 2012
UPLOAD · Letter from the SECMar 12, 2012
S-1 · Registration statementFeb 14, 2012

Open IPO · From the cover of the final prospectus (424B4) filed Nov 9, 2012

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue16.0K17.0K23.0K8.00K23.0K46.6K52.8K44.2K129.0K303.5K
Gross profit-16.0K-17.0K-23.0K-8.00K-23.0K-46.6K-52.8K-44.2K-129.0K-303.5K
Research and development21.2M14.1M17.3M15.1M9.21M6.61M6.65M4.21M2.33M770.4K
Selling, general and administrative16.0M13.5M14.0M12.6M11.3M8.00M10.6M7.22M4.86M6.48M
Operating income-37.1M-27.6M-31.4M-27.7M-20.5M-14.6M-17.3M-11.4M-7.65M-7.97M
Depreciation and amortization16.0K17.0K23.0K8.00K23.0K47.0K52.8K44.2K129.0K303.5K
EBITDA-37.1M-27.6M-31.4M-27.7M-20.5M-14.6M-17.2M-11.4M-7.52M-7.67M
Interest expense8.00K85.0K938.8K00192.8K0
Income before tax-34.8M-25.5M-30.1M-27.0M-20.6M-17.8M-17.2M-11.4M-8.12M-6.37M
Income tax000000000-1.76M
Net income-34.8M-25.5M-30.1M-27.0M-20.6M-17.8M-17.2M-11.4M-8.12M-6.37M
Earnings per share, basic-4.04-3.04-0.24-0.21-0.18-1.97-2.03-5.50-10.97-2.16
Earnings per share, diluted-4.04-3.04-0.24-0.21-0.18-1.97-2.03-5.50-10.97-2.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents41.3M71.1M88.5M110.9M136.4M39.6M12.6M10.4M7.22M3.03M
Short-term investments55.0K55.0K
Receivables-1.43M743.0K1.07M634.9K739.7K518.1K358.3K194.3K
Inventory1.49M5.25M2.60M1.92M972.3K619.8K305.9K0
Current assets45.6M74.5M92.2M118.2M141.2M42.8M14.3M11.5M7.90M3.25M
Property, plant and equipment20.0K21.0K34.4K54.5K11.5K55.1K
Goodwill00
Total assets47.6M76.4M96.3M123.5M141.3M42.8M14.5M11.7M8.16M4.14M
Accounts payable4.29M679.0K806.0K2.96M1.72M1.59M293.2K353.3K334.9K254.3K
Current liabilities8.26M4.97M5.24M5.57M3.13M15.7M1.32M2.92M1.23M1.05M
Long-term debt00
Total debt18.1K50.5K
Total liabilities8.26M4.97M5.24M5.57M3.13M15.7M1.33M2.92M1.23M1.05M
Shareholders' equity39.4M71.5M91.0M118.0M138.1M27.2M13.2M8.81M6.94M3.10M
Shares outstanding8.61M8.61M125.3M126.6M126.6M47.5M9.13M5.85M2.65M3.79M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-29.8M-21.0M-20.9M-20.8M-16.5M-11.6M-9.13M-8.96M-6.59M-5.37M
Capital spending-23.0K-19.0K-14.0K-27.0K-9.00K-9.00K-7.63K-110.9K-110.9K-9.21K
Free cash flow-29.8M-21.0M-21.0M-20.8M-16.5M-11.6M-9.14M-9.07M-6.59M-5.38M
Cash from investing-23.0K-19.0K-14.0K-4.73M-9.00K-9.00K-7.63K-110.9K-110.9K-9.21K
Cash from financing03.67M-1.48M0113.3M38.6M11.3M12.3M10.8M4.70M
Dividends paid-4.50M00
Share buybacks0-1.48M0-5739.61M11.3M12.3M10.0M4.70M
Change in cash-29.8M-17.4M-22.4M-25.5M96.8M27.0M2.20M3.22M4.19M-687.9K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 10, 2026ResultsSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportOct 9, 2026Material contractSEC
8-K · Current reportSep 29, 2026Current reportSEC
8-K · Current reportSep 18, 2026Current reportSEC
8-K · Current reportAug 7, 2026ResultsSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
424B5 · ProspectusJun 12, 2026Offer documentSEC
8-K · Current reportJun 11, 2026Material contractSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
8-K · Current reportMay 8, 2026Current reportSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
8-K · Current reportMay 8, 2026Meeting outcomeSEC
8-K · Current reportApr 16, 2026Current reportSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
ARS · Annual report to shareholdersMar 30, 2026Annual reportSEC
DEF 14A · Proxy statementMar 30, 2026Meeting noticeSEC
10-K · Annual reportMar 25, 2026Annual reportSEC
8-K · Current reportMar 25, 2026Current reportSEC
PRE 14A · Preliminary proxy statementMar 20, 2026Meeting noticeSEC
8-K · Current reportFeb 20, 2026Material contractSEC
424B5 · ProspectusFeb 20, 2026Offer documentSEC
424B3 · ProspectusFeb 20, 2026Offer documentSEC
8-K · Current reportFeb 17, 2026Current reportSEC
8-K · Current reportFeb 11, 2026Current reportSEC
4/A · Change in ownership, amendedJan 30, 2026Insider tradeSEC
8-K · Current reportJan 26, 2026Meeting outcomeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
8-K · Current reportJan 9, 2026ResultsSEC
8-K · Current reportJan 6, 2026Current reportSEC
DEF 14A · Proxy statementDec 22, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 12, 2025Meeting noticeSEC
8-K · Current reportDec 4, 2025Current reportSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 21, 2025Insider tradeSEC
8-K · Current reportOct 14, 2025Management or board changeSEC
8-K · Current reportSep 26, 2025Current reportSEC
8-K · Current reportSep 8, 2025Current reportSEC
8-K · Current reportAug 21, 2025Current reportSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
8-K · Current reportMay 9, 2025Meeting outcomeSEC
8-K · Current reportApr 7, 2025Current reportSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
ARS · Annual report to shareholdersMar 26, 2025Annual reportSEC
DEF 14A · Proxy statementMar 26, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 26, 2025Offer documentSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
8-K · Current reportMar 25, 2025ResultsSEC
8-K · Current reportMar 12, 2025Current reportSEC
8-K · Current reportFeb 24, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
8-K · Current reportFeb 4, 2025Current reportSEC
8-K · Current reportDec 10, 2024Current reportSEC
8-K · Current reportNov 19, 2024Material contractSEC
424B5 · ProspectusNov 19, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
8-K · Current reportNov 4, 2024Current reportSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
8-K · Current reportJul 2, 2024Management or board changeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 24, 2024Other filingsSEC
DEF 14A · Proxy statementMay 23, 2024Meeting noticeSEC
CORRESP · Letter to the SECMay 21, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 21, 2024Other filingsSEC
DEL AMMay 14, 2024Other filingsSEC
S-3 · Registration statementMay 13, 2024Offer documentSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
ARS · Annual report to shareholdersMay 10, 2024Annual reportSEC
PRE 14A · Preliminary proxy statementMay 10, 2024Meeting noticeSEC
4 · Change in ownershipApr 11, 2024Insider tradeSEC
8-K/A · Current report, amendedApr 1, 2024ResultsSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
8-K · Current reportApr 1, 2024ResultsSEC
8-K · Current reportMar 18, 2024Current reportSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 14, 2024Insider tradeSEC
8-K · Current reportMar 12, 2024Management or board changeSEC
4 · Change in ownershipNov 17, 2023Insider tradeSEC
4/A · Change in ownership, amendedNov 15, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 15, 2023Insider tradeSEC
4 · Change in ownershipNov 15, 2023Insider tradeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
8-K · Current reportNov 9, 2023Management or board changeSEC
3 · Initial statement of ownershipOct 16, 2023Insider tradeSEC
8-K · Current reportOct 6, 2023Management or board changeSEC
8-K · Current reportSep 28, 2023Current reportSEC
8-K · Current reportAug 30, 2023Current reportSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
8-K · Current reportJul 13, 2023Current reportSEC
8-K · Current reportJun 28, 2023Current reportSEC
8-K · Current reportJun 23, 2023Current reportSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 5, 2023Insider tradeSEC
8-K · Current reportJun 1, 2023Management or board changeSEC
8-K · Current reportMay 22, 2023Current reportSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
4 · Change in ownershipMay 5, 2023Insider tradeSEC
4 · Change in ownershipMay 5, 2023Insider tradeSEC
4 · Change in ownershipMay 5, 2023Insider tradeSEC
4 · Change in ownershipMay 5, 2023Insider tradeSEC
4 · Change in ownershipMay 5, 2023Insider tradeSEC
8-K · Current reportMay 4, 2023Meeting outcomeSEC
DEFA14A · Additional proxy materialApr 26, 2023Meeting noticeSEC
8-K · Current reportApr 26, 2023Current reportSEC
8-K · Current reportApr 4, 2023Current reportSEC
ARS · Annual report to shareholdersMar 30, 2023Annual reportSEC
DEF 14A · Proxy statementMar 30, 2023Meeting noticeSEC
10-K · Annual reportMar 22, 2023Annual reportSEC
8-K · Current reportMar 22, 2023ResultsSEC
8-K · Current reportMar 13, 2023Current reportSEC
4 · Change in ownershipMar 6, 2023Insider tradeSEC
4 · Change in ownershipMar 6, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2022Quarterly reportSEC
8-K · Current reportNov 7, 2022ResultsSEC
8-K · Current reportOct 7, 2022Current reportSEC
10-Q · Quarterly reportAug 8, 2022Quarterly reportSEC
8-K · Current reportAug 8, 2022ResultsSEC
SC 13G · Big-stake noticeJul 8, 2022Big-stake noticeSEC
8-K · Current reportJul 7, 2022Current reportSEC
8-K · Current reportJul 1, 2022Current reportSEC
8-K · Current reportJun 6, 2022Current reportSEC
4 · Change in ownershipMay 16, 2022Insider tradeSEC
4 · Change in ownershipMay 16, 2022Insider tradeSEC
4 · Change in ownershipMay 16, 2022Insider tradeSEC
4 · Change in ownershipMay 16, 2022Insider tradeSEC
4 · Change in ownershipMay 16, 2022Insider tradeSEC
8-K · Current reportMay 16, 2022Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2022Quarterly reportSEC
8-K · Current reportMay 9, 2022ResultsSEC
DEF 14A · Proxy statementApr 11, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 1, 2022Meeting noticeSEC
4 · Change in ownershipFeb 28, 2022Insider tradeSEC
4 · Change in ownershipFeb 28, 2022Insider tradeSEC
10-K · Annual reportFeb 28, 2022Annual reportSEC
8-K · Current reportFeb 28, 2022ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 9, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 4, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 13, 2022Big-stake noticeSEC
10-Q · Quarterly reportNov 15, 2021Quarterly reportSEC
8-K · Current reportNov 15, 2021ResultsSEC
8-K · Current reportOct 6, 2021Meeting outcomeSEC
DEFA14A · Additional proxy materialSep 14, 2021Meeting noticeSEC
8-K · Current reportSep 8, 2021Meeting outcomeSEC
10-Q · Quarterly reportAug 13, 2021Quarterly reportSEC
8-K · Current reportAug 13, 2021ResultsSEC
DEF 14A · Proxy statementAug 9, 2021Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 29, 2021Meeting noticeSEC
4 · Change in ownershipJul 7, 2021Insider tradeSEC
8-K · Current reportMay 18, 2021Management or board changeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
4 · Change in ownershipMay 18, 2021Insider tradeSEC
10-Q · Quarterly reportMay 14, 2021Quarterly reportSEC
8-K · Current reportMay 14, 2021ResultsSEC

This page holds 200 of 643 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Atossa Therapeutics, Inc.’s releases · as of Jul 31, 2026

Common shares
9,979,298
Fully diluted
9,979,298

Fully diluted

LineSharesAs of
Common shares9,979,298Jul 31, 2026

Warrants and options

Lot
Warrants · expiry not stated

Share count over time

CountShares
Jul 31, 20269,979,298

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Vanguard417K4.2%US$814KNo changeNov 13, 2026
BlackRock169K1.7%US$329K+4,263Nov 13, 2026
Renaissance Technologies110K1.1%US$214K−22,136Nov 12, 2026
Geode Capital95,5770.96%US$186K+3,195Nov 6, 2026
State Street39,7610.40%US$77,534No changeNov 12, 2026
UBS30,5080.31%US$59,490−52,112Nov 10, 2026
Ameriprise27,4120.27%US$53,454−231KNov 16, 2026
Susquehanna21,5130.22%US$41,950+5,939Nov 16, 2026
Northern Trust20,2130.20%US$39,415−36Nov 16, 2026
Millennium14,8670.15%US$28,991−31,641Nov 16, 2026
All 33 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Morgan Stanley12,3450.12%US$24,073No changeNov 13, 2026
RBC4,8850.05%US$10,000+2,891Nov 16, 2026
Barclays2,5580.03%US$4,988NewNov 6, 2026
Jones Financial Companies Lllp2,0610.02%US$3,916No changeNov 13, 2026
NewEdge Advisors, LLC1,1270.01%US$2,198NewNov 13, 2026
Osaic Holdings, Inc.587<0.01%US$1,157No changeNov 12, 2026
Rydar Equities, Inc.333<0.01%US$819NewOct 13, 2026
Rockefeller Capital Management L.P.333<0.01%US$649No changeNov 13, 2026
Harbour Investments, Inc.176<0.01%US$343+66Nov 9, 2026
SBI Securities Co., Ltd.148<0.01%US$289No changeOct 21, 2026
Wells Fargo145<0.01%US$283−83Nov 16, 2026
BFC Planning, Inc.124<0.01%US$242NewNov 13, 2026
TD103<0.01%US$230No changeOct 16, 2026
BNP Paribas87<0.01%US$170No changeNov 12, 2026
NBH Bank69<0.01%US$135NewNov 5, 2026
Allworth Financial LP66<0.01%US$129NewNov 17, 2026
Bolton Securities Corporation50<0.01%US$98No changeNov 12, 2026
Fidelity35<0.01%US$68NewNov 10, 2026
IFP Advisors, Inc29<0.01%US$57NewOct 16, 2026
Caitong International Asset Management Co., Ltd8<0.01%US$16+2Oct 29, 2026
Bogart Wealth, LLC5<0.01%US$10No changeNov 10, 2026
Clearstead Advisors, LLC4<0.01%US$8No changeNov 6, 2026
Citigroup Inc1<0.01%US$2NewNov 4, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund256K2.6%US$494KNo changeJun 30, 2026
Columbia Small Cap Value Discovery Fund201K2.0%US$417K+12,200Jul 31, 2026
Vanguard Extended Market Index Fund99,0710.99%US$191K+12,651Jun 30, 2026
Fidelity Extended Market Index Fund46,4090.47%US$243K−372May 31, 2026
Columbia Variable Portfolio - Small Cap Value Discovery Fund36,3830.36%US$70,219−1,500Jun 30, 2026
iShares Micro-Cap ETF29,2030.29%US$56,362NewJun 30, 2026
Fidelity Total Market Index Fund14,3820.14%US$75,218No changeMay 31, 2026
Fidelity Series Total Market Index Fund12,6430.13%US$66,123+1,406May 31, 2026
Vanguard Balanced Index Fund6,5390.07%US$12,620No changeJun 30, 2026
Fidelity Nasdaq Composite Index Fund4,2110.04%US$22,024No changeMay 31, 2026
All 12 holders
HolderSharesOf the companyValueChangeAs of
1290 VT Micro Cap Portfolio1,9860.02%US$3,833NewJun 30, 2026
Diversified Equity Alpha Master Portfolio952<0.01%US$1,837No changeJun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Richard I. Steinhart
Other companies: BioXcel Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Mar 7, 2018); Actinium Pharmaceuticals, Inc. (Delaware) (Director · Since at least Nov 8, 2013); MELA Sciences Inc (Chief Financial Officer · May 14, 2010 – Aug 5, 2013 · Past); TG Therapeutics, Inc. (Director · Mar 25, 2008 – Mar 3, 2010 · Past)
Director · Since at least Mar 1, 2014
Christopher Benjamin
Other companies: Quantum Materials Corp (Director · Jun 30, 2011 – Oct 2, 2015 · Past)
Chief Financial Officer · Nov 7, 2012 – Nov 7, 2012 · Past
Gregory L Weaver
Other companies: Altimmune, Inc. (Chief Financial Officer · Since at least Nov 11, 2024)
Former EVP, CFO, & Director, Director · May 17, 2019 – Nov 15, 2023 · Past
Kyle Guse
Other companies: Plus Therapeutics, Inc. (Director · Since at least Apr 18, 2025)
CFO, Gen Counsel and Secretary · Jan 4, 2013 – Mar 2, 2023 · Past
Ben R ChenSr. VP of Glob. Reg. Affairs · Apr 1, 2014 – Apr 1, 2014 · Past
Christopher S DestroSVP, Sales and Marketing · May 6, 2014 – Mar 16, 2015 · Past
Claudia LopezVice President, Clinical Product Development · Nov 5, 2024 – Nov 5, 2026 · Past
Heather ReesChief Financial Officer · Oct 6, 2023 – May 15, 2025 · Past
H Lawrence RemmelDirector · Since at least Nov 7, 2012
Janet R. ReaSenior Vice President, R&D · Since at least Nov 12, 2025
All 18 people
PersonSeat
Jonathan FinnDirector · Since at least Nov 8, 2023
Mark DanielChief Financial Officer · Since at least Oct 14, 2025
Peter J CarbonaroSr. Vice President, Operations · May 6, 2014 – May 6, 2014 · Past
Scott YoumansChief Operating Officer · Sep 1, 2015 – Sep 1, 2015 · Past
Shu-Chih ChenDirector · Since at least Nov 7, 2012
Stephen J GalliDirector · Since at least Nov 7, 2012
Steven QuayChief Executive Officer · Since at least Nov 7, 2012
Tessa CiglerDirector · Since at least Mar 9, 2024

Open People

Log in to ask 6ix AI your own questions about Atossa Therapeutics, Inc.